Shop on Impakter Eco
  • Women
  • Men
  • Kids
  • Beautycare
  • Home & Living
  • Food & Drinks
  • Pets
Impakter
  • Shop Eco
  • Culture
    • Art
    • Cinema
    • Entertainment
    • Literature
    • Music
    • Photography
  • Style
    • Architecture
    • Design
    • Fashion
    • Foodscape
    • Lifestyle
  • Society
    • Business
    • Environment
    • Foreign Affairs & Politics
    • Health
    • Tech
    • Science
    • Start-up
  • Impact
    • Eco Life
    • Circular Economy
    • COP26
    • CityLife
      • Copenhagen
      • San Francisco
      • Seattle
      • Sydney
    • Sustainability Series
      • SDGs Series
      • Shape Your Future
      • 2030: Dream or Reality
    • Philanthropy
      • United Nations
      • NGO & Charities
      • Essays
    • Your Voice
      • Empower Earth
      • Empower Equality
  • SUSTAINABILITY INDEX
  • Startup-Hub
    • Companies
    • Investors
    • Organisations
    • Jobs
    • Events
  • Partners
  • About
    • Team
    • Global Leaders
    • Contributors
    • Write for Impakter
    • IMPAKTER Italy
    • Republishing Content
    • Permissions and Copyright
    • Privacy Policy
    • Contact
No Result
View All Result
Impakter
No Result
View All Result
Home Society Health

Columbia University Researchers Use AI to Develop Treatment for Coronavirus

Robert Florida - Columbia UniversitybyRobert Florida - Columbia University
March 27, 2020
in Health, Society, Start-up, Tech
Share on FacebookShare on Twitter

Columbia University is at the frontier between AI and biotech, especially in coronavirus research. Two graduates of the Data Science Institute (DSI) at Columbia University – Andrew Satz and Brett Averso – are using AI in coronavirus research, relying on computational design to accelerate the discovery of treatments for the coronavirus.

Andrew Satz and Brett Averso are Chief Executive Officer and Chief Technology Officer, respectively, of EVQLV, a startup creating algorithms capable of computationally generating, screening, and optimizing hundreds of millions of therapeutic antibodies. They apply their technology to discover treatments most likely to help those infected by the virus responsible for COVID-19. The machine learning algorithms rapidly screen for therapeutic antibodies with a high probability of success.

Conducting antibody discovery in a laboratory typically takes years; it takes just a week for the algorithms to identify antibodies that can fight against the virus.

Expediting the development of a treatment that could help infected people is critical according to Satz, who is a 2018 DSI alumnus and 2015 graduate of Columbia’s School of General Studies.

“We are reducing the time it takes to identify promising antibody candidates,” says Satz. “Studies show it takes an average of five years and a half-billion dollars to discover and optimize antibodies in a lab. Our algorithms can significantly reduce that time and cost.”

Speeding up the first stage of the process—antibody discovery—goes a long way toward expediting the discovery of a treatment for COVID-19. After EVQLV performs computational antibody discovery and optimization, it sends the promising antibody gene sequences to its laboratory partners.

Laboratory technicians then engineer and test the antibodies, a process that takes a few months thanks to AI, as opposed to several years. Antibodies found to be successful will move onto animal studies and, finally, human studies.

In the picture: Brett Averso and Andrew Satz, CEO and CTO at EVQLV. Photo Credit: EVQLV

Given the international urgency to combat the coronavirus, Satz says it may be possible to have a treatment ready for patients before the end of 2020.

“What our algorithms do is reduce the likelihood of drug-discovery failure in the lab,” he adds. “We fail in the computer as much as possible to reduce the possibility of downstream failure in the laboratory. And that shaves a significant amount of time from laborious and time-consuming work.”

Averso, who is also a 2018 DSI alumnus, says some of the antibodies EVQLV is designing are intended to prevent the coronavirus from attaching to the human body. “The right-shaped antibodies bind to proteins that sit on the surface of human cells and the coronavirus, similar to a lock and key. Such binding can prevent the proliferation of the virus in the human body, potentially limiting the effects of the disease.”

He also noted that the scientific community and the biotech industry are galvanized to forge collaborations that bring about therapeutics, diagnostics, and vaccines as quickly as possible.


RELATED ARTICLES: COVID-19: Link with Air Pollution? Italy’s and China’s Experience |Coronavirus and the Rise of China |Mismanagement of the Coronavirus emergency and the Italian Model |How to Get your workplace ready for Coronavirus – WHO Rules |

EVQLV collaborates with Immunoprecise Antibodies (IPA), a company focused on the discovery of therapeutic antibodies. The collaboration will accelerate the effort to develop therapeutic candidates against COVID-19.

EVQLV will identify and screen hundreds of millions of potential antibody treatments in only a few days—far beyond the capacity of any laboratory. IPA will produce and test the most promising antibody candidates.

Satz and Averso, who met while students at DSI, are deeply committed to using “data for good.” The pair have worked together for several years at the intersection of data science and health care and formed EVQLV in December 2019 to use AI to accelerate the speed at which healing is discovered, developed, and delivered.

The company has already grown to 12 team members with skills ranging from machine learning and molecular biology to software engineering and antibody design, cloud computing, and clinical development.

Both DSI graduates typically put in 100-hour workweeks because they are passionate about and committed to using data science to “help heal those in need.”

“We are building a company that sits at the frontiers of AI and biotech,” Satz says. “We are hard at work accelerating the speed at which healing is discovered and delivered and could not ask for a more fulfilling mission.” 

In the picture: The map of Covid-19 spread. Photo Credit: John Hopkins University


EDITOR’S NOTE: The opinions expressed here by Impakter.com columnists are their own, not those of Impakter.com.
Tags: AIColumbia UniversityCoronavirusCOVID-19EVQLVHealthcaremachine learningstartup
Previous Post

The Importance of Connecting People With Nature in Times of Social Isolation

Next Post

Jupe Health Launches Mobile ICU Units

Robert Florida - Columbia University

Robert Florida - Columbia University

Related Posts

G7 Facing Putin’s Threats of Nuclear War and the World Food and Energy Crisis
Politics & Foreign Affairs

G7 Facing Putin’s Threats of Nuclear War and the World Food and Energy Crisis

June 27, 2022
The 1977 White House Climate Memo That Should Have Changed the World
Environment

The 1977 White House Climate Memo That Should Have Changed the World

June 25, 2022
How Britain’s Bill of Rights Would Affect Human Rights, International Law, and the UK
Equal Rights

How Britain’s Bill of Rights Would Affect Human Rights, International Law, and the UK

June 24, 2022
Next Post
Jupe Health Launches Mobile ICU Units

Jupe Health Launches Mobile ICU Units

Recent News

Apple Leather: The Game Changer Among Leather Alternatives

Apple Leather: The Game Changer Among Leather Alternatives

June 28, 2022
G7 Facing Putin’s Threats of Nuclear War and the World Food and Energy Crisis

G7 Facing Putin’s Threats of Nuclear War and the World Food and Energy Crisis

June 27, 2022
The 1977 White House Climate Memo That Should Have Changed the World

The 1977 White House Climate Memo That Should Have Changed the World

June 25, 2022
impakter-logo-light

Impakter informs you through the eco news site and empowers your sustainable lifestyle with its eco products marketplace.

Visit here IMPAKTER ECO for your eco products needs.

Registered Office Address

32 Lots Road, London
SW10 0QJ, United Kingdom


IMPAKTER Limited

Company number: 10806931

Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).


Office Hours - Monday to Friday

9.30am - 5.00pm CEST


Email

stories [at] impakter.com

About Us

  • Team
  • Contributors
  • Privacy Policy
  • Contact
  • Partners

By Audience

  • Lifestyle
  • Green Finance
  • Culture
  • Society
  • Style
  • Impact

Impakter Platforms

  • Media
  • Up
  • Index
  • Eco for Sellers
  • Impakter Pro

© 2022 IMPAKTER. All rights reserved.

No Result
View All Result
  • Culture
  • Style
  • Society
  • Impact
  • ECO Products Shop – Try now!
  • INDEX – Sustainability Index
  • UP – Startup Hub
  • About
    • Partners
    • Team
    • Contact
    • Privacy Policy
Impakter.com uses cookies to enhance your experience when visiting the website and to serve you with advertisements that might interest you. By continuing to use this site, you agree to our use of cookies. Visit our Privacy and Cookie Policy.